Sun Pharma Advanced Research Company (SPARC) has received an approval from US Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg).
ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat.
Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 439.45, up by 27.70 points or 6.73% from its previous closing of Rs. 411.75 on the BSE.
ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat.
Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 439.45, up by 27.70 points or 6.73% from its previous closing of Rs. 411.75 on the BSE.
No comments:
Post a Comment